Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
|Articles|July 2, 2022
- Pharmaceutical Technology, July 2022
- Volume 46
- Issue 7
- Pages: 12
Robotic Injectable Drug Processor
Author(s)Pharmaceutical Technology Editors
Steriline’s Robotic Nest Filling Machine is designed to minimize human intervention in aseptic processing of injectable drugs.
Steriline’s Robotic Nest Filling Machine is designed to aseptically process injectable drugs in a more efficient, safe, and flexible manner than traditional alternatives. By minimizing human intervention, the machine aims to produce a higher quality product with fewer operator mistakes.
The machine automatically adapts its process to recipes that have been registered in its database. Once a specific container is registered in this database, special sensors in the machine can detect the type and capacity of the containers. These sensors can also identify any non-compliant pieces and manage them without technician intervention, reducing waste and downtime.
The machine is capable of processing vials, ampoules, cartridges, syringes, and bags, and can handle toxic or non-toxic products in both liquid and powder form. It can be equipped with laminar air flow, open and closed restricted access barriers, and isolator barrier systems.
Articles in this issue
about 4 years ago
Getting Proactive with Pharma Packagingabout 4 years ago
Advancing Accessibility through Point-of-Use Manufacturingabout 4 years ago
Formulating Biologics: A Learning Curveabout 4 years ago
Automating Biopharma Manufacturingabout 4 years ago
Challenges to Formulation Development for Highly Potent APIsabout 4 years ago
Prefilled Syringes Show Strong Growthabout 4 years ago
Material Management and the Impact on Extractables and Leachablesabout 4 years ago
Trends in International Arbitration: The Fallout from COVID-19Related to this article
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.